Article ID Journal Published Year Pages File Type
1912669 Journal of Geriatric Oncology 2011 7 Pages PDF
Abstract

ObjectivesThis study investigated the effect of capecitabine–oxaliplatin (XELOX) on functional independence in patients aged ≥ 70 years with histologically proven metastatic colorectal cancer (mCRC).Materials and methodsPatients received capecitabine 750 mg/m2 bid d1–14 + oxaliplatin 90 mg/m2 d1, every 3 weeks; doses were increased to 1000 and 120 mg/m2, respectively, in the absence of significant toxicity. The primary endpoint was stabilization/improvement of Katz Activities of Daily Living (ADL) scale.ResultsSixty patients were enrolled. ADL was stabilized/improved in 36/40 patients (90%) after 3 cycles, and in 25/27 patients (93%) after 6 cycles. Capecitabine and oxaliplatin doses were increased in 31% of patients. The objective response rate was 37% (1 complete and 21 partial responses). Toxicity included grade 3/4 diarrhea (13%), neurotoxicity (grade 1/2 in 68%, grade 3/4 in 2%), and grade 3/4 anemia (7%).ConclusionThis study demonstrates the feasibility of XELOX in elderly mCRC patients, with no impairment of independence among patients who remained on therapy.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Authors
, , , , , , , , , ,